| 名称 | AZD1080 |
| 描述 | AZD1080 is a selective, orally active, brain permeable GSK3 inhibitor. |
| 细胞实验 | 3T3 fibroblasts are engineered to stably express four-repeat tau protein. These cells have high endogenous levels of GSK3 that is able to phosphorylate tau protein constitutively. This phosphorylation is inhibited by LiCl. After treatment with different compounds, cultures are washed twice with 5 mM MgCl2-PBS. Extracts for Western blot analysis are prepared by homogenizing cells in ice-cold extraction buffer consisting of 20 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM NaF, 1% Triton X-100, 1 mM sodium orthovanadate, 10 mM EDTA, and protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 10 μg/ml leupeptin, and 10 μg/ml pepstatin). The samples are homogenized at 4 °C, and protein content is determined by Bradford method. Total protein (25 μg) is electrophoresed on 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The experiments are performed using the following primary antibodies: tau Ser(P)-396, 1:1000; Tau5, 1:1000; and anti-GSK3β, 1:1000. The filters are incubated with the antibody at 4 °C overnight in 5% nonfat dried milk. A secondary antibody (1:5000), followed by ECL detection reagents are used for immunodetection. Quantitation of immunoreactivity is performed by densitometric scanning.(Only for Reference) |
| 激酶实验 | Kinase Assay: GSK3 scintillation proximity assay is done. The competition experiments are carried out in duplicate with 10 concentrations of the inhibitor in clear-bottomed microtiter plates. The biotinylated peptide substrate biotin-AAEELDSRAGS(PO3H2)PQL, is added at a final concentration of 2 μM in an assay buffer containing 6 milliunits of recombinant human GSK3 (equal mix of both α and β), 12 mM MOPS, pH 7.0, 0.3 mM EDTA, 0.01% β-mercaptoethanol, 0.004% Brij 35, 0.5% glycerol, and 0.5 μg of bovine serum albumin/25 μl and preincubated for 10–15 min. The reaction is initiated by the addition of 0.04 μCi of [γ-33P]ATP and unlabeled ATP in 50 mM Mg(Ac)2 to a final concentration of 1 μM ATP and assay volume of 25 μl. Blank controls without peptide substrate are used. After incubation for 20 min at room temperature, each reaction is terminated by the addition of 25 μl of stop solution containing 5 mM EDTA, 50 μM ATP, 0.1% Triton X-100, and 0.25 mg of streptavidin-coated SPA beads corresponding to 35 pmol of binding capacity. After 6 h the radioactivity is determined in a liquid scintillation counter. |
| 体外活性 | AZD1080逆转小鼠的认知缺陷并拯救其功能失调的突触.口服AZD1080抑制大鼠脑中tau蛋白磷酸化,在峰浓度下脑/血浆暴露比率为0.5-0.8.急性口服AZD1080抑制外围GSK3的活性,剂量依赖性降低磷酸化糖原合成酶和总糖原合成酶的比率,在最高剂量为10mol/kg时达到平均最大抑制效果49％. |
| 体内活性 | AZD1080抑制表达人类tau的细胞中的tau磷酸化,IC50为324 nM。AZD1080抑制人GSK3α和GSK3β,Ki 值分别为6.9 nM和31 nM,对cdk2、cdk5、cdk1和Erk2表现出> 14倍的选择性。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 40 mg/mL (119.63 mM), Sonication is recommended.
|
| 关键字 | AZD-1080 | Glycogen synthase kinase-3 | AZD1080 | Glycogen synthase kinase 3 | Inhibitor | GSK-3 | AZD 1080 | inhibit |
| 相关产品 | Cromolyn sodium | Ginsenoside Rg2 | 4-Chloro-2'-bromoacetophenone | CHIR-99021 HCl | AT7519 | 5-Bromoindole | GSK-3 Inhibitor 5 | GSK 3 Inhibitor IX | SNS-032 | Cyanoacetohydrazide | CHIR-99021 | 1-Azakenpaullone |
| 相关库 | 神经保护化合物库 | 抑制剂库 | 经典已知活性库 | 已知活性化合物库 | 激酶抑制剂库 | 抗衰老化合物库 | 神经退行性疾病化合物库 | 药物功能重定位化合物库 | 抗癌临床化合物库 | 抗癌药物库 |
![aladdin 阿拉丁 A126905 2-羟基-3-[5-[(吗啉-4-基)甲基]吡啶-2-基]-1H-吲哚-5-甲腈(AZD1080) 612487-72-6 ≥98%](https://img.chemicalbook.com/SupplyImg/2024-04-18/Large/202404180842486985165.jpeg)
